SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-24-030232
Filing Date
2024-06-27
Accepted
2024-06-27 07:01:52
Documents
7
Period of Report
2024-08-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A def14a2024.htm DEF 14A 3084148
2 GRAPHIC avalo-logoxblk.jpg GRAPHIC 48586
3 GRAPHIC avalotherapeuticsinc_vxp001.jpg GRAPHIC 155481
4 GRAPHIC avalotherapeuticsinc_vxp002.jpg GRAPHIC 117130
5 GRAPHIC investordeck_pipelinechart.jpg GRAPHIC 492886
6 GRAPHIC pvpgraph_netlossa.jpg GRAPHIC 55386
7 GRAPHIC pvpgraph_tsra.jpg GRAPHIC 49107
  Complete submission text file 0001628280-24-030232.txt   4348256
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37590 | Film No.: 241075291
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)